Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
US11192860B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Inventors
Key dates
| Filing date | Jul 11, 2018 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Jul 11, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.